Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer's PF-0496582, AbbVie's upadacitinib and Incyte's topical ruxolitinib have the most potential upside if approved
Read MoreWith no current FDA approved biologics for the treatment of non-radiographic axial spondyloarthropathy, overall penetration of biologics/JAKs is significantly lower than for ankylosing spondylitis; however, when these agents are prescribed, brand usage closely mirrors the ankylosing spondylitis indication, according to a new publication by Spherix Global Insights
Read MoreThe majority of patients started on Xeljanz have failed multiple biologics, but some gastroenterologists see the brand securing a role in the pre-biologic space in the near future, according to the latest quarterly report from Spherix Global Insights
Read More